Algernon's drug pipeline is growing. We are targeting multiple different disease processes. If ifenprodil outperforms the best in class medication currently used for chronic cough in pulmonary fibrosis, that will trigger a bidding war. Big pharma will be lined up at the door and the market cap of this company could be worth billions no problem. That's because these guys would be walking into multi-millions, if not billions in sales. How could you not want to acquire shares in this stock flying under the radar, given that they've already shown in their animal models it does outperform the best drug on the market. Like they said in the Biopub release, after you show that it works, most drugs go on to die in the safety profile category. We don't have to worry about that either! It's been used in humans before safely! And that's just chronic cough... If ifenprodil decrease acute lung injury secondary to acute respiratory distress syndrome caused by coronavirus in south korean patients (where it's a legal drug), again, you will have multi-billions being offered by big pharma and instantly we could see share price in the hundreds of dollars range.
I mean I don't know about you guys... but that's why I am here... not for a couple thousand bucks... but for the big show.
News 
Market Data 
Discover 
